WANDA BEARING
920002
CG MED EQUIP.
838810
SUZHOUBEARING
430418
4
COCYBER
835207
5
Guangdong Create Century Intelligent Equipment Group Corporation
300083
US Stock MarketDetailed Quotes
BIOA BioAge Labs
- 4.190
- +0.010+0.24%
Close Feb 26 16:00 ET
- 4.190
- 0.0000.00%
Post 17:32 ET
150.21MMarket Cap-2.02P/E (TTM)
4.250High4.080Low116.26KVolume4.180Open4.180Pre Close485.08KTurnover1.11%Turnover RatioLossP/E (Static)35.85MShares26.62052wk High0.48P/B44.00MFloat Cap3.85052wk Low--Dividend TTM10.50MShs Float26.620Historical High--Div YieldTTM4.07%Amplitude3.850Historical Low4.172Avg Price1Lot Size
Trending Stocks
Discussing
Big Tech’s earnings season in full swing! Nvidia is the only one left
On Thursday, $Amazon (AMZN.US)$ stock fell after the firm reported Q4 adjusted earnings of $1.86/share, vs estimates of $1.50/share, on reve
Moo Earnings
Feb 2 12:39
AMZN earnings preview: Grab rewards by guessing the opening price!
BioAge Labs Stock Forum
Alzheimer's Drug Deal: How BioArctic's $1.3B Bristol Myers Agreement Could Transform Treatment
BioArctic AB announced the completion of its global license agreement with Bristol Myers Squibb after receiving U.S. Federal Trade Commission clearance. The agreement, initially announced on December 19, 2024, grants Bristol Myers Squibb worldwide development and commercialization rights for BAN1503 and BAN2803, part ...
Milestone Achievement: Alzheimer's Breakthrough Leqembi Reaches €200M Sales, Triggering Major Payout
Pelosi's new holdings have doubled $Tempus AI (TEM.US)$ value in just a few weeks, and $Firefly Neuroscience (AIFF.US)$'s inclusion in NVIDIA's Connect program has also caused its stock price to soar.
In addition, DeepSeek's rapid rise has boosted the AI application sector, particularly in medicine/healthcare. Cathie Wood believes medical AI is undervalued, with untapped pot...
BioAge Labs Announces Company Updates on APJ, NLRP3, and Platform Programs
Tuesday, 28th January at 9:00 am
Advancement of next-generation APJ agonists with discontinuation of azelaprag
Nomination of NLRP3 inhibitor BGE-102 as a development candidate, with initial Ph1 clinical data anticipated by end of 2025
Expansion of discovery efforts based on insights from BioAge's platform, including a target identification collaboration with Novartis and a newly announced antibo...
No comment yet